Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
2(29%)
Results Posted
50%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
4
57%
Ph phase_2
3
43%

Phase Distribution

4

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Active, not recruiting1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 23 (42.9%)

Trials by Status

active_not_recruiting114%
terminated114%
completed457%
recruiting114%

Recent Activity

2 active trials
Showing 5 of 7
active_not_recruitingphase_2

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

NCT03808558
recruitingphase_1

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

NCT05743621
completedphase_2

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT04906421
terminatedphase_1

TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

NCT02980029
completedphase_2

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

NCT03032484
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03808558Phase 2

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Active Not Recruiting
NCT05743621Phase 1

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Recruiting
NCT04906421Phase 2

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Completed
NCT02980029Phase 1

TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

Terminated
NCT03032484Phase 2

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Completed
NCT04352361Phase 1

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

Completed
NCT02223247Phase 1

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7